National Eye Institute (NEI)
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, National Eye Institute (NEI) sits in the top decile of US sponsors by registered trial count (#145 of 15,742 sponsors by registered trial count).
National Eye Institute (NEI): 221 sponsored US clinical trials, 18 recruiting.
National Eye Institute (NEI) sponsors 221 registered US clinical trials on ClinicalTrials.gov, 18 of them currently recruiting, and 179 completed. 11 of these trials are in Phase 3-4 (later-stage) and 86 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Age-related Macular Degeneration, with 8 trials.
Top-decile sponsor footprint
National Eye Institute (NEI) ranks in the top decile of sponsors by registered trial count (#145 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
179 of 196 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (91.3%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
221 total, page 4 of 5
EYE001 to Treat Retinal Tumors in Patients With Von Hippel-Lindau Syndrome
NCT00056199
Laser and Antioxidant Treatment of Diabetic Macular Edema
NCT00055042
Biological Markers in Retinal Vasculitis
NCT00050492
Laser and Medical Treatment of Diabetic Macular Edema
NCT00050479
Dynamic Light Scattering and Keratoscopy for Corneal Examination
NCT00050466
Saccadic Eye Movements in Patients With Niemann-Pick Type C Disease
NCT00316498
Celecoxib to Treat Macular Degeneration in Patients Receiving Photodynamic Therapy
NCT00043680
Daclizumab Injections to Treat Non-Infectious Sight-Threatening Uveitis
NCT00043667
Prevalence and Risk of Cataracts in Granulocyte Donors
NCT00042627
Differences in Genes and Proteins in Active and Controlled Uveitis
NCT00357266
Laser and Medical Treatment of Diabetic Macular Edema
NCT00027287
Vitamin E to Treat Uveitis-Associated Macular Edema
NCT00021645
Identification and Treatment of Feeder Vessels in Macular Degeneration
NCT00018070
A Novel Acuity Testing Method
NCT00013936
Evaluation and Treatment of Patients With Inherited Eye Diseases
NCT00011817
Evaluation and Treatment of Patients With Corneal and External Diseases
NCT00008541
Fluocinolone Implant to Treat Macular Degeneration
NCT00008515
Dynamic Light Scattering Device (DLS) Study of Age-Related Changes in the Lens and Cataracts
NCT00007215
Evaluation and Treatment of Pediatric Eye Diseases
NCT00006422
Lutein for Age-Related Macular Degeneration
NCT00006202
Evaluation and Treatment of Patients With Inflammatory Eye Diseases
NCT00006188
Cause of Pigment Dispersion Syndrome
NCT00005919
Magnetic Resonance Imaging to Study the Normal Eye
NCT00005911
Evaluation and Treatment of Patients With Retinal Disease
NCT00005784
Blood Factors and Diabetic Retinopathy
NCT00005761
Genetic Study of Age-Related Macular Degeneration
NCT00357578
Cornea Donor Study
NCT00006411
Development of the Eye Motor System During the First 7 Months of Life in Infants With and Without a Family History of Cross-Eye
NCT00001143
Effect of Pregnancy on Uveitis
NCT00001867
Eye Muscle Surgery to Treat Congenital Nystagmus
NCT00001866
HAT in Eye Complications of Behcet's Disease
NCT00001865
Amblyopia (Lazy Eye) Treatment Study
NCT00001864
Complications of Age-Related Macular Degeneration Prevention Trial
NCT00000167
Leflunomide to Treat Uveitis
NCT00001863
TNRF:Fc to Treat Eye Inflammation in Juvenile Rheumatoid Arthritis
NCT00001862
Screening for Studies on Nystagmus and Strabismus
NCT00001861
Vascular Endothelial Growth Factor (VEGF) in Uveitis
NCT00001738
New Cysteamine Eye Drops Formulation to Treat Corneal Crystals in Cystinosis
NCT00001736
Cyclosporin Implant to Treat Uveitis
NCT00001737
Gene Therapy for Gyrate Atrophy
NCT00001735
Screening for NEI Clinical Studies
NCT00001734
Screening for Studies on Retinovascular Diseases
NCT00001733
Screening for Studies on Inherited Eye Diseases
NCT00001732
Treatment of Dry Eye Syndrome With Cyclosporin A Eye Drops
NCT00001731
Test of QLS Device to Detect Early Cataracts
NCT00001617
Phase I Study of Corticosteroid Treatment of Ill-Defined Choroidal Neovascularization in Age-Related Macular Degeneration
NCT00001615
The Safety and Efficacy of Chicken Type II Collagen on Uveitis Associated With Juvenile Rheumatoid Arthritis
NCT00001614
Cataract Surgery to Obtain Human Lens Material for the Study of Nuclear Cataracts
NCT00001613
Long-Term Follow-Up of Patients Enrolled in the Early Treatment Diabetic Retinopathy Study (ETDRS)
NCT00001612
Immune Activity Against CVM Retinitis
NCT00001611
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 62 |
| Phase 2 | 24 |
| Phase 3 | 11 |
Therapeutic Areas
What is open in the National Eye Institute (NEI) pipeline
18 recruiting of 221 indexed (8% open); 179 completed (81%).
Phase mix: 11 late (III/IV) vs 86 early (I/II) (early-phase heavy).
Top condition: Age-related Macular Degeneration (8 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
National Eye Institute (NEI): open-pipeline peers nationwide
Peers matched on 221 registered trials and 8% open enrollment, not the therapeutic-area sidebar.
National Eye Institute (NEI) sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 221 trials (± recruiting share)
- Otsuka Pharmaceutical Development & Commercialization · 221 trials · 4% recruiting
- Florida State University · 219 trials · 21% recruiting
- Penn State University · 219 trials · 17% recruiting
- University of Louisville · 217 trials · 21% recruiting
Sponsors near 8% open enrollment (± trial volume)
- GE Healthcare · 8% recruiting · 99 trials
- HealthPartners Institute · 8% recruiting · 146 trials
- Oregon Research Institute · 8% recruiting · 62 trials
- Arcutis Biotherapeutics · 8% recruiting · 25 trials
Related
What to do with this National Eye Institute (NEI) page
221 registered trials is a research-attention snapshot, not an endorsement of National Eye Institute (NEI) or any single study.
- 18 of National Eye Institute (NEI)'s trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Age-related Macular Degeneration is the condition National Eye Institute (NEI) studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Age-related Macular Degeneration trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. National Eye Institute (NEI) pipeline card: 221 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.